

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

Data Insights: Covid-2019 Monitor

Friday, February 18, 2022



For more information contact us: Donald Luskin: 214 550 2121 <u>don@trendmacro.com</u> Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2022 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

Kolling out the vaccines in the US and the world											
Administered	Cumu	Ilative					To	day	Immunity	Full	Partial
Doses	563,818,191						+1.708	million	US	64.2%	76.0%
Boosters	93,596,790						+0.207	million	UK	71.5%	77.0%
	One dose		% Pop Immune		nune	% рор	New immune today		France	77.1%	80.0%
Total population	260,142,070		78%	220,673,811		66%	+0.366	million	Spain	82.1%	87.7%
Age 12 to 17	17,207,706		68%		14,617,672	58%	+0.025	million	Germany	74.2%	75.4%
Age 18 to 64	1/5,438,/83		86%	1.	48,669,182	73%	+0.261	million	Italy	77.8%	83.7%
Age 65 and over	58,133,277		100%	50,277,835		92%	+0.038	million	Australia	79.0%	85.0%
3%									Israel	65.8%	72.1%
0,0									Japan	00.4 <i>%</i>	80.6%
Moderna	State		Best	t					Δfrica	11.5%	16.8%
38%	At least part	At least partial immunity							India	54.2%	68.8%
Pfizer	AK 58.3% Pfizer 59% as % population Full immunity as % population "Immunity" = two doses		Midd	le					Brazil	71.3%	81.5%
59%									China	85.1%	87.7%
AK			Wors	st					Global data differ	s due to source	s, timing
68.3%					WI		As of Feb 17		Γ	ME	
60.7%					70.9%					89.1%	
					64.3%		_			78.1%	
WA	ID	MT	ND	MN	IL	MI		NY	VT	NH	
79.4%	60.1%	64.3%	64.3%	74.1%	75.9%	65.8%		88.5%	92.7%	95.0%	
71.1%	52.8%	55.7%	54.3%	67.8%	67.1%	58.9%		75.1%	79.9%	69.5%	
OR	NV	WY	SD	IA	IN	OH	PA	NJ	MA		
76.7%	73.7%	57.8%	74.6%	67.1%	60.5%	62.7%	82.9%	88.6%	95.0%		
68.4%	59.4%	<u>50.4%</u>	59.6%	60.9%	53.8%	57.4%	66.6%	/3.9%	//.3%	DI	1
01 /10/	71.00/	70 10/	ED 20/		CE 10/	64 00/	04 20/				
01.4% 70.0%	71.0% 62.1%	70.1% 60.0%	62.2%	00.1% 54.0%	00.1% 56.2%	04.0%	04.2% 71.7%	04.0%	93.5% 77.5%	90.0%	
70.070	A7	NM	62.2 /0	AR	JU.2 /0	NC	SC	73.0 %	DF	00.2 /0	
	71.1%	85.5%	73.2%	65.5%	61.1%	81.9%	66.2%	94.6%	81.4%		
	59.7%	69.2%	59.8%	53.2%	53.2%	59.1%	55.5%	71.0%	67.2%		
			OK	LA	MS	AL	GA				
			69.8%	60.0%	58.6%	61.7%	64.1%				
HI			55.8%	52.3%	50.6%	50.0%	53.4%				
85.9%			TX					FL		PR	
76.9%			70.5%					77.8%		94.8%	
			59.7%					65.7%	l l	80.8%	
The demographics of		lan									
The demographics of	US vaccinal	lion	0.0%				40000				
70%66.2% of fe	66,2% of females immunized			90% 61.3% of whites immunized				14.6% of ag	e <12 immuni	zed	
60% - 62.0% of ma	%62:0% of mates			80% 51.9% of African Americans				% 55.3% 12-15			
			70% 66.0% of Hispanics				80% -	60.6% 16-	7		
50%			60%				70% -	70% 61.6% 18-24			
40%			50%				60% 65.4% 5-39				
			30%				50% -	73.3%404	8		
30%			40%				40% -	79.9% 50-6	4////		
20%			30%				30% -	91.0% 65-7	Æ (
			20%				20%	85.3% 754	(
10%			10%			10%			/		
							10/0				
8 2 2 2 a	22 22	8° 8° 8° 8° 8° 8° 8° 8°				-20 -	N N	2.22 2	- A A		
1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612, 1. 612,			16/2016/2016/2016/2016/2016/2016/2016/20				0/20/20/20/20/20/20/20/20/20/20/20/20/20		10/20/20/20/20	612,1012.	
VV V A 60 8	211 JI 1 101 81 201 21 JI				21 JI BI OI 81 201 37. JY.						

D II. 1.41

Source: <u>CDC</u>, <u>CDC</u>, <u>Our World in Data</u>, TrendMacro calculations





















Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

Recommended reading

Another Potential Covid-19 Lab Leak Clue

Wall Street Journal February 17, 2022

Catholic Schools' Good Covid Year

Wall Street Journal February 17, 2022

<u>Citation impact and social media visibility of Great</u> Barrington and John Snow signatories for COVID-19

<u>strategy</u> John P Ioannidis *British Medical Journal* February 9, 2022

It's time to get our lives back and declare the end to COVID-19 pandemic

Rep. Ami Bera *Sacramento Bee* February 15, 2022

FDA Executive Officer Exposes Close Ties Between Agency and Pharmaceutical Companies: 'Almost a Billion Dollars a Year Going into FDA's Budget from the People we Regulate'

Project Veritas February 16, 2022

Meme of the day



Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP



The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale*



The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*

Source: Johns Hopkins, TrendMacro calculations



Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Johns Hopkins, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Act Now, TrendMacro calculations

From Ground Zero to the Rio Grande

Cases: 7-day average and daily Deaths: Daily



Source: Johns Hopkins, TrendMacro calculations





Patient zero... and then everyone else

Cases: 7-day average and daily Deaths: Daily

Source: Johns Hopkins, TrendMacro calculations

Impact in the largest economies Cases: 7-day average and daily



Source: Johns Hopkins, TrendMacro calculations

Impact in The Anglosphere Cases: 7-day average and daily Deaths: Daily

120,000 3.0% South Korea As of Feb 17 100,000 2.5% 1,755,806 cases cumulative 338.68 bp of population infected +109,828 cases today Daily new cases and deaths 60,000 40,000 40,000 1.40 bp of population fatalities 2.0% 41.8 median population age Cume fatality rate 0.41% 2-week fatality rate 0.21% 1.5% 37.9% total population immunized 1.0% 7,283 deaths cumulative +45 deaths today 20,000 0.5% 0.0% Jul '20 Nov '20 Jan '21 Jan '20 Mar '20 May '20 Sep '20 Mar '21 May '21 Jul '21 Sep '21 Nov '21 Jan '22 25,000 0.6% Singapore 533,425 cases cumulative 0.5% 935.24 bp of population infected 20,000 +18,545 cases today 0.20 bp of population fatalities Daily new cases and deaths 0.4% 34.6 median population age Cume fatality rate 0.17% 15,000 98.2% Omicron variant share 88.5% total population immunized 0.3% 2-week fatality rate 0.13% 10,000 0.2% 930 deaths cumulative +4 deaths today 5,000 0.1% 0.0% Mar '20 Jan '22 Jan '20 May '20 Jul '20 Sep '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Nov '21 60,000 14% Sweden 12% 50,000 2389.41 bp of population infected 16.57 bp of population fatalities 2,418,560 cases cumulative 10% Daily new cases and deaths +4,097 cases today 40.9 median population age 40,000 96.2% Omicron variant share ase fatality rate 8% Cume fatality rate 0.69% 74.3% total population immunized 30,000 6% 2-week fatality rate 0.24% 20,000 4% 16,768 deaths cumulative +52 deaths today 10,000 2% 0% May '20 Jul '20 Sep '20 Nov '20 Jan '21 Jan '20 Mar '20 Mar '21 May '21 Jul '21 Sep '21 Nov '21 Jan '22 Source: Johns Hopkins, TrendMacro calculations

Impact in other hot-spots Cases: 7-day average and daily Deaths: Daily

Impact in the BRICs ex-China Cases: 7-day average and daily Deaths: Daily

Impact in the Middle East and Africa

Cases: 7-day average and daily Deaths: Daily

Source: Johns Hopkins, TrendMacro calculations